DPPE-PEG350

DPPE-PEG350 is a CD1d-dependent lipid antagonist thus blocking the ERK phosphorylation pathway in iNKT cells[1][2]. DPPE-PEG350 is a PEG lipid functional end group used in the synthesis of liposomes (LPs) for the design of conjugated polymer nanoparticles.

Product Specifications

CAS Number

474922-84-4

Product Name Alternative

16:0 PEG350 PE; 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol) -350] (ammonium)

UNSPSC

12352211

Target

CD1; Liposome

Type

Biochemical Assay Reagents

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Others

Assay Protocol

https://www.medchemexpress.com/16-0-peg350-pe.html

Solubility

10 mM in DMSO

Smiles

O=C(NCCOP(O)(OC[C@@H](COC(CCCCCCCCCCCCCCC)=O)OC(CCCCCCCCCCCCCCC)=O)=O)OCCOC.N.[n]

Molecular Formula

(C2H4O) nC39H76NO10P.H3N

Molecular Weight

350 (Average)

References & Citations

[1]Xiao H, et al. Regulation of microglia polarization via mannose receptor-mediated delivery of siRNA by ligand-functionalized DoGo LNP. RSC Adv. 2021 Oct 4;11 (52) :32549-32558.|[2]Sommonte F, et al. In-House Innovative "Diamond Shaped" 3D Printed Microfluidic Devices for Lysozyme-Loaded Liposomes. Pharmaceutics. 2022 Nov 16;14 (11) :2484.|[3]Li Y, Kanellakis P, Hosseini H, Cao A, Deswaerte V, Tipping P, Toh BH, Bobik A, Kyaw T. A CD1d-dependent lipid antagonist to NKT cells ameliorates atherosclerosis in ApoE-/- mice by reducing lesion necrosis and inflammation. Cardiovasc Res. 2016 Feb 1;109 (2) :305-17. |[4]Lombardi V, Stock P, Singh AK, Kerzerho J, Yang W, Sullivan BA, Li X, Shiratsuchi T, Hnatiuk NE, Howell AR, Yu KO, Porcelli SA, Tsuji M, Kronenberg M, Wilson SB, Akbari O. A CD1d-dependent antagonist inhibits the activation of invariant NKT cells and prevents development of allergen-induced airway hyperreactivity. J Immunol. 2010 Feb 15;184 (4) :2107-15.